title: A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: E
authors.initials: E
authors.lastname: Edson-Heredia
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: S
authors.initials: S
authors.lastname: Banerjee
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: B
authors.initials: B
authors.lastname: Zhu
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: T
authors.initials: T
authors.lastname: Maeda-Chubachi
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: G S
authors.initials: GS
authors.lastname: Cameron
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: W
authors.initials: W
authors.lastname: Shen
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Heffernan
authors.affiliation: Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: K B
authors.initials: KB
authors.lastname: Gordon
authors.affiliation: St. Louis University School of Medicine, St. Louis, MO, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Leonardi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C549079:ixekizumab